Clinical uses of pegylated pharmaceuticals in oncology
Author:
- 1 January 2002
- journal article
- research article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 28, 7-11
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast CancerJournal of Clinical Oncology, 2002
- Pegylation: engineering improved pharmaceuticals for enhanced therapyCancer Treatment Reviews, 2002
- Novel effects with polyethylene glycol modified pharmaceuticalsCancer Treatment Reviews, 2002
- Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcomaEuropean Journal of Cancer, 2001
- Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2001
- Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving ChemotherapyJournal of Clinical Oncology, 2000
- A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humansExperimental Hematology, 1999
- Polyethylene Glycol-Liposomal DoxorubicinDrugs, 1997
- Polyethylenglykol-umhülltes (pegyliertes) liposomales DoxorubicinDrugs, 1997
- FilgrastimDrugs, 1994